WO1999006058A1 - Fracciones hidrosolubles de phlebodium decumanum y su empleo como complemento nutricional en pacientes de sida y cancer - Google Patents
Fracciones hidrosolubles de phlebodium decumanum y su empleo como complemento nutricional en pacientes de sida y cancer Download PDFInfo
- Publication number
- WO1999006058A1 WO1999006058A1 PCT/ES1998/000220 ES9800220W WO9906058A1 WO 1999006058 A1 WO1999006058 A1 WO 1999006058A1 ES 9800220 W ES9800220 W ES 9800220W WO 9906058 A1 WO9906058 A1 WO 9906058A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- exply
- rhizome
- extract
- water
- decumanum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Definitions
- This invention relates to a water-soluble fraction obtained from the fronds of a cultivated variety of Phlebodium decumanum, purified and standardized, identified as EXPLY-37, to formulations containing it and to the use thereof as nutritional supplements of general or 0 application, and, in particular, for patients presenting with general deterioration and weakening and cachectic syndrome, as in AIDS patients and oncological patients.
- Such formulations can also be used during the application of antiretroviral drugs in AIDS patients and 5 conventional cancer treatments (surgery and / or radio and chemotherapy) to improve their effectiveness and reduce the side effects of such treatments. They also have utility 0 in the recovery of patients undergoing such treatments.
- Cachexia is a complex syndrome characterized by loss of appetite and weight, generalized weakening, anemia and asthenia. This syndrome is associated with a metabolic imbalance and manifests itself in the form of weight loss and widespread deterioration: the body is unable to maintain the adequate energy supply and consumes its own fat and muscle protein reserve.
- HIV human immunodeficiency virus
- the cachectic syndrome that manifests itself in HIV infection is characterized by progressive weight loss and increased weakness, often associated with fever and diarrhea.
- the causes of these alterations are complex and multifactorial and appear to be related to inadequate diets, malabsorption phenomena, metabolic imbalances and activity of some cytokines, such as tumor necrosis factor (TNF), 11-1 (interleukin-1), 11 -6 (interleukin-6) and ⁇ -IFN (alpha-interferon) [SE Weinroth et al., Infect. Agents Dis. 1995, 4, 76-94].
- TNF tumor necrosis factor
- 11-1 interleukin-1
- 11 -6 interleukin-6
- ⁇ -IFN alpha-interferon
- cachectic impairment appears to be associated, in a high proportion, with the death of cancer patients. This proportion is considered by some authors as 30-70%. Many cancer patients die with a marked weight loss and a
- tumor necrosis factor ⁇ TNF- ⁇
- 11-1 interleukin-1
- the fern known for years as Polypodium leucotomos has historically been used by Honduran natives, in the form of an infusion of frond and rhizome, for the treatment of malignant tumors, rheumatoid arthritis and psoriasis.
- Horvath et al. [Nature 1967, 214, 1256-1258] demonstrated the antitumor effect in vivo and in vivo of an aqueous extract of said fern. Since that date, a water-soluble fraction obtained from the fronds of Polypodium leucotomos has been extensively studied, having described its immunomodulatory / immunosuppressive profile and its free antioxidant and anti-radical properties [M.D.
- the present invention provides a water-soluble fraction of the fronds of a cultivated variety of Phlebodium decumanum, purified and standardized, identified as EXPLY-37, its obtaining and its use in the elaboration of useful formulations as a nutritional supplement.
- This invention is directed, although not limited, to the obtaining a water-soluble fraction of the fronds of a cultivated variety of Phlebodium decumanum, purified and standardized, identified as EXPLY-37, as well as obtaining formulations based on EXPLY-37, and its use as a nutritional supplement in AIDS patients and cancer
- the formulations of the invention can also be used during the application of antiretroviral drugs in AIDS patients, and of conventional oncological treatments (surgery and / or radio and chemotherapy), to improve their efficacy and reduce side effects. in the 0 recovery of patients undergoing such treatments.
- EXPLY-37 is the registered trademark, owned by HELSINT 5 SAL, and used to designate Phlebodium Extract decumanum of Lake Yojoa. No. 37 corresponds to the extraction procedure chosen among the many tested for obtaining said extract from the fronds of the plant and is based on what was previously published in GB 2,024,622-A, GB 2,075,834-A, ES P8902092 and recently collected in WO 96/25139.
- the sporulated fronds of Phlebodium decumanum, dried and crushed, are slipped by treatment with petroleum ether, methylene chloride or mixtures of petroleum ether / 0- methylene chloride, and are subsequently extracted with a mixture of methanol / water.
- An alternative method consists of pre-extraction with a mixture of methanol / water and subsequent delipulation with petroleum ether, methylene chloride or mixtures of petroleum ether / methylene chloride.
- the removal of methanol under reduced pressure provides the water-soluble fraction that is purified by passage through a mixed ion exchange column, treatment with activated carbon, sodium metabisulfite and filtration.
- Example 1 describes a procedure for obtaining a water-soluble fraction of Phlebodium decumanum fronds identified as EXPLY-37 as well as a typical composition of said fraction [Table 1].
- the EXPLY-37 brand has been requested by HELSINT SAL 5 to distinguish the extract of Phlebodium decumanum grown in Lake Yojoa and obtained by this procedure and differentiate it from other extracts that could be obtained from wild varieties of Phlebodi um decumanum from other origins.
- Q From the rhizome a water-soluble fraction (or extract), purified and standardized, is also obtained by the following procedure. The rhizome once devoid of villi, washed with an antiseptic solution and deionized water, dried, crushed and extracted with a mixture of methanol / water.
- Example 2 describes a procedure for obtaining a water-soluble fraction, or extract, of rhizome of Phlebodi um decumanum as well as a typical composition of said fraction [Table 2].
- the invention provides formulations comprising EXPLY-37, useful as a nutritional supplement.
- the formulations may contain, in addition to EXPLY-37, rhizome and / or water-soluble fraction of rhizome.
- the formulations are suitable for oral administration, may be solid or liquid and may be presented in the form of powders, in the form of gelatin capsules (hard or soft) or in the form of syrup.
- this mixture of EXPLY-37 and rhizome of Crushed and homogenized Phlebodium decumanum in the form of dry powder, can be used to fill hard gelatin capsules that may contain amounts of said solid mixture between 100 and 500 mg.
- the weight ratio [crushed and homogenized rhizome]: EXPLY-37 present in the mixture is between 4: 1 and 1: 1.
- this mixture of EXPLY-37, rhizome powder and rhizome extract of Phlebodium decumanum, in the form of dry powder can be used to fill hard gelatin capsules that may contain amounts of said solid mixture between 100 and 500 mg
- the weight ratio [EXPLY-37 + rhizome extract]: [crushed and homogenized rhizome] present in the mixture is between 4: 1 and 1: 1.
- formulations can be presented in the form of soft gelatin capsules and syrups.
- Soft gelatin capsules containing EXPLY-37 Dilution of EXPLY-37 to a suitable viscosity allows filling of soft gelatin capsules by injection and obtaining capsules that may contain 50 to 750 mg of EXPLY-37 .
- Soft gelatin capsules containing EXPLY-37 and rhizome extract of Phlebodium decumanum These capsules can be obtained by a procedure comprising the following steps: - preparation of a homogeneous mixture of EXPLY-37 and rhizome extract of Phlebodium decumanum in varying proportions within a wide range (50:50 to 95: 5); and adequate dilution of the mixture for injection into soft gelatin capsules with a total extract content [EXPLY-37 + rhizome extract] of 50 to 750 mg per capsule.
- Preferred formulations may contain between 50 and 500 mg of EXPLY-37 per gram.
- a syrup can be obtained by homogenizing EXPLY-37 and rhizome extract of Phlebodi um decumanum in varying proportions (50:50 to 95: 5) with the following components : fluid extract of Sacharum officinarum, fluid extract of Glycyrrhiza glabra, and citric acid.
- Preferred formulations are those containing between 50 and 500 mg of total extract [EXPLY-37 + rhizome extract] per gram.
- a syrup can be obtained by incorporating EXPLY-37 into an aqueous solution containing as excipients: - invert sugar,
- Preferred formulations are those that contain between 20 and 500 mg of EXPLY-37 per milliliter.
- Preferred formulations are those containing between 20 and 500 mg of [EXPLY-37 + rhizome extract] per milliliter.
- the formulations based on EXPLY-37 provided by this invention are useful as a nutritional supplement of general application.
- these formulations are suitable in the treatment of malnutrition, weight loss, general deterioration and cachectic syndrome in AIDS patients [see the results obtained in AIDS patients ( 0 Clinical Results: I. Patients with advanced HIV infection) ], as well as during the application of antiretroviral drugs in AIDS patients, and in the treatment of cancer patients who have general weakening and cachectic deterioration, such as advanced cancer patients, since these
- formulations slow down and reverse the cachexia causing a general improvement of the patients that allows the effective application of the appropriate treatments.
- the formulations based on EXPLY-37 of this invention can also be used as an adjuvant in conventional cancer treatments (surgery
- the sporulated fronds of Phlebodium decumanum are dried for 1 week in chambers in which air is blown at 40-50 ° C. Once dried, the leaves are crushed until a mixture of small particles and fine dust is obtained.
- 100 kilograms (kg) or crushed and dried leaf are extracted 3 times with 400 liters (L) of a methanol / deionized water mixture (7: 3) at the temperature of 40 ° C for 12 hours.
- Hydrometanolic extracts are combined and concentrated under reduced pressure at 40 ° C until complete removal of methanol.
- a fine aqueous suspension is obtained which is treated 3 times with an equal volume of a non-polar solvent, preferably petroleum ether or mixtures of petroleum ether and dichloromethane, to remove residual lipids.
- the water-soluble fraction is purified by passing through an ion exchange resin, subsequent treatment with sodium metabisulfite and Q filtration. The final concentration under reduced pressure to a water content of 20% provides between 5 and 10% of
- the extracts are combined and the mixture is evaporated at 40 ° C and 25 mm until complete removal of methanol.
- the cloudy aqueous solution is extracted with an equal volume of methylene chloride or mixtures of methylene chloride and petroleum ether (twice).
- the aqueous phase is subsequently treated with activated carbon to an absorbance of 0.5 to 1.5 to 290 nanometers (nm) and concentrated at 40 ° C and 25 mm pressure to a final solids concentration of 80%.
- nm nanometers
- Phlebod ⁇ um decumanum Purified and standardized
- Capsules of EXPLY-37 and rhizome 50 kg of fresh rhizomes of Phlebodium decumanum devoid of villi are immersed, successively, in dilute aqueous solution of active chlorine, deionized water, absolute ethanol and sterile deionized water. They are then dried in a fluid bed dryer at 40-50 ° C for 2 hours. They are ground and sifted until a fine powder is obtained.
- EXPLY-37 enriched capsules and rhizome Following a procedure similar to that described in the Example 3, the final mixture is prepared with 25.5 kg of crushed, sieved and dried rhizome, and 18.5 kg of EXPLY-37. Once dry, hard gelatin capsules containing 440 mg of powder are prepared.
- EXPLY-37 capsules, rhizome and rhizome extract By a procedure analogous to that described in Example 3, a final mixture is prepared containing 26.8 kg of crushed, sieved and dried rhizome, 10 kg of EXPLY-37 and 3, 2 kg of rhizome extract. Capsules with 400 mg of dry powder are prepared.
- the relative proportions of EXPLY-37 and rhizome extract can vary between wide limits (50:50 to 95: 5).
- a homogeneous mixture of 7.8 kg of Sacharum officinarum fluid extract and 190 g of Glycyrrhiza fluid extract is prepared in a stainless steel reactor / mixer equipped with a paddle stirrer at stirring speed of 20 revolutions per minute (rpm) glabra (licorice). 10 g of citric acid are incorporated into the homogeneous mass. Finally, with stirring and at 37 ° C, 2 kg of EXPLY-37 are added until homogenization. A syrup containing 200 mg of EXPLY-37 per gram is obtained.
- EXPLY-37 syrup and rhizome extract The steps described in Example 6 are followed. At the end 1 kg of EXPLY-37 and 1 kg of rhizome extract are added, obtaining a syrup with a total extract concentration of 200 mg / g. Syrups with a composition of 50 to 500 mg of total extract per gram can also be obtained, the total extract being the mixture in varying proportions (50:50 to 95: 5) of EXPLY-37 and rhizome extract.
- Syrup concentration 200 mg / mL, expressed in EXPLY-37 or in EXPLY-37 + rhizome extract. Following the same technique, syrups have been prepared containing a wide range of concentrations (20 to 500 g / ml).
- Honduran patients aware of the existence of the Yojoa Lake plantation have been requesting some compassionate remedy to improve their status.
- HIH decided to prepare various formulations, examples of which are included in this patent application, and administer them as nutritional, dietary and energizing supplement to those patients who They requested.
- a second group of patients, subject to the new more flexible inclusion criteria is being treated with EXPLY-37 capsules and rhizome, analogous to those described in Example 4, at a dose of 6-12 capsules / day.
- the first 4 patients who are in their third week of treatment have generally experienced an improvement similar to that already observed in the previous groups: immediate recovery of appetite, regular and progressive recovery of body weight, improvement of the quality of life and resumption of personal and professional activities in those cases in which there had been an abandonment of them.
- EXPLY-37 in different formulations, in cancer patients with different types of tumors and in different stages, either in the course of conventional cancer treatments or after the application of such treatments, has allowed to demonstrate the effectiveness of such formulations in:
- Table 5 summarizes some representative cases in which the positive evolution of the patient's condition is associated with the continued use of EXPLY-37. Table 5 Results in cancer patients
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98935039A EP1040834A1 (en) | 1997-07-30 | 1998-07-29 | HYDROSOLUBLE FRACTIONS OF $i(PHLEBODIUM DECUMANUM) AND USE THEREOF AS NUTRITIONAL COMPLEMENTS IN AIDS AND CANCER PATIENTS |
US09/269,497 US6228366B1 (en) | 1998-07-29 | 1998-07-29 | Water-soluble fractions of Phlebodium decumanum and its use as nutritional supplement in AIDS and cancer patients |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP9701693 | 1997-07-30 | ||
ES09701693A ES2124675B1 (es) | 1997-07-30 | 1997-07-30 | "formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum, y su uso en el tratamiento del sindrome caquectico en enfermos de sida". |
ES009801139A ES2137900B1 (es) | 1998-06-02 | 1998-06-02 | Empleo de formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum como complemento nutricional en el tratamiento del sindrome caquectico en pacientes oncologicos. |
ESP9801139 | 1998-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999006058A1 true WO1999006058A1 (es) | 1999-02-11 |
Family
ID=26155082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES1998/000220 WO1999006058A1 (es) | 1997-07-30 | 1998-07-29 | Fracciones hidrosolubles de phlebodium decumanum y su empleo como complemento nutricional en pacientes de sida y cancer |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1040834A1 (es) |
WO (1) | WO1999006058A1 (es) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3395223A (en) * | 1965-05-13 | 1968-07-30 | Carter Wallace | Fern extract for treating gastric ulcers |
ES471572A1 (es) * | 1978-07-07 | 1979-01-16 | Conrad Ltd | Procedimiento de obtencion de fraccion polar natural con ac-tividad antipsoriatica |
ES8104315A1 (es) * | 1980-04-02 | 1981-04-16 | Conrad Ltd | Un procedimiento de obtencion de un extracto de las fraccio-nes polares de los helechos de la familia polypodiaceae. |
EP0503208A1 (en) * | 1991-03-08 | 1992-09-16 | Maracuyama International, S.A. | Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns |
ES2068163B1 (es) * | 1994-05-06 | 1995-09-01 | Esp Farmaceuticas Centrum Sa | Procedimiento de obtencion de un extracto vegetal con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes. |
ES2088770A1 (es) * | 1995-02-23 | 1996-09-01 | Esp Farmaceuticas Centrum Sa | Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes. |
WO1997023233A1 (en) * | 1995-12-21 | 1997-07-03 | Parbold Investments N.V. | Biologically active compositions and their use |
-
1998
- 1998-07-29 EP EP98935039A patent/EP1040834A1/en not_active Withdrawn
- 1998-07-29 WO PCT/ES1998/000220 patent/WO1999006058A1/es not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3395223A (en) * | 1965-05-13 | 1968-07-30 | Carter Wallace | Fern extract for treating gastric ulcers |
ES471572A1 (es) * | 1978-07-07 | 1979-01-16 | Conrad Ltd | Procedimiento de obtencion de fraccion polar natural con ac-tividad antipsoriatica |
ES8104315A1 (es) * | 1980-04-02 | 1981-04-16 | Conrad Ltd | Un procedimiento de obtencion de un extracto de las fraccio-nes polares de los helechos de la familia polypodiaceae. |
EP0503208A1 (en) * | 1991-03-08 | 1992-09-16 | Maracuyama International, S.A. | Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns |
ES2068163B1 (es) * | 1994-05-06 | 1995-09-01 | Esp Farmaceuticas Centrum Sa | Procedimiento de obtencion de un extracto vegetal con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes. |
ES2088770A1 (es) * | 1995-02-23 | 1996-09-01 | Esp Farmaceuticas Centrum Sa | Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes. |
WO1997023233A1 (en) * | 1995-12-21 | 1997-07-03 | Parbold Investments N.V. | Biologically active compositions and their use |
Non-Patent Citations (2)
Title |
---|
HORVATH A. ET AL.: "Metabolic Effects of Calagualine an Antitumoral Saponine of Polipodium leucotomos", NATURE,, no. 214, June 1967 (1967-06-01), LONDRES,, pages 1256 - 1258, XP002943812 * |
See also references of EP1040834A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1040834A1 (en) | 2000-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2533273C2 (ru) | Композиции с экстрактами плодов шиповника и способ получения экстрактов плодов шиповника | |
ES2857566T3 (es) | Extracto de Eurycoma longifolia y su uso para mejorar y/o estimular el sistema inmunitario | |
ES2894362T3 (es) | Un proceso para mejorar la bioactividad de los extractos de ashwagandha | |
KR101839721B1 (ko) | 바이칼레인을 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물 | |
JP5612670B2 (ja) | セレンおよび/または亜鉛共存下でのアロニア種抽出物を含む免疫刺激組成物 | |
EP2682123B1 (en) | Biologically active food additive for normalizing the function of the thyroid gland | |
CN111565758A (zh) | 包含花色素苷-岩藻依聚糖复合物为活性成分的免疫增强剂、免疫治疗抗癌剂和抗癌治疗不良反应缓解剂 | |
KR20170125343A (ko) | 확장된 에너지를 제공하는 조성물 및 그 사용 방법 | |
JP2008214299A (ja) | パパイヤおよび白花蛇舌草の水溶性抽出成分を含む癌の予防、治療または改善のための組成物 | |
RU2171284C2 (ru) | Композиция ингредиентов для приготовления лечебно-профилактического бальзама | |
WO1999006058A1 (es) | Fracciones hidrosolubles de phlebodium decumanum y su empleo como complemento nutricional en pacientes de sida y cancer | |
US9895406B2 (en) | Homeopathic remedies and methods for enhancing weight loss | |
US20100003364A1 (en) | Reduced-hangover alcoholic beverage comprising turmeric | |
RU2074244C1 (ru) | Композиция ингредиентов для бальзама "авиценна" | |
RU2743292C1 (ru) | Средство для лечения желчекаменной и мочекаменной болезней | |
KR20230039856A (ko) | 복합 진세노사이드 조성물을 포함하는 항염증 조성물 | |
WO2022157810A1 (en) | A synergistic herbal immunomodulatory formulation | |
US6228366B1 (en) | Water-soluble fractions of Phlebodium decumanum and its use as nutritional supplement in AIDS and cancer patients | |
EP3824899A1 (en) | Inflammatory cytokine production inhibitor | |
RU2805149C1 (ru) | Сбор гепатопротекторный для лечения заболеваний печени | |
RU2761598C1 (ru) | Сухой безалкогольный напиток | |
RU2156129C1 (ru) | Биологически активное средство тонизирующего действия | |
KR20180083821A (ko) | 진세노사이드 화합물 k를 이용한 세포독성 항암제 부작용 억제용 조성물 | |
RU2160596C1 (ru) | Сбор лекарственных растений, обладающий противовирусным, противомикробным и иммуномодулирующим действиями | |
KR20130119856A (ko) | 찹쌀수추출물을 함유하는 장(腸)보호를 위한 항(抗)염증 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CA MX UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/002922 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09269497 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998935039 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1998935039 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998935039 Country of ref document: EP |